Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1

Conditions

Sarcoma 37Rhabdomyosarcoma 25Sarcoma, Ewing 18Dendritic Cell Sarcoma, Interdigitating 17Lymphoma 13Neuroectodermal Tumors, Primitive, Peripheral 10Lymphoma, Large B-Cell, Diffuse 10Neuroblastoma 8Malignant mesenchymal tumor 8HIV Infections 8Sarcoma, Kaposi 7Osteosarcoma 7Burkitt Lymphoma 7Acquired Immunodeficiency Syndrome 7Desmoplastic Small Round Cell Tumor 6Leukemia 5Wilms Tumor 4Neoplasms 4Lymphoma, Non-Hodgkin 4Central Nervous System Neoplasms 4Brain Neoplasms 4Astrocytoma 4Rhabdomyosarcoma, Embryonal 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Liposarcoma 3Gliosarcoma 3Glioblastoma 3Fibrosarcoma 3Bone Neoplasms 3

Interventions

pevonedistat 1Vincristine 1Rituximab 1Prednisone 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Acromesomelic dysplasia, Maroteaux type × Vincristine × Sarcoma × Clear all
NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡